Alexion Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.

Gregory Coffey

Andrew Steele

Jiajia Feng

Anjali Pandey

Pamela B Conley

John T Curnutte

Matthew Birrell

Glenn Michelson

Janet Leeds

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and/or have relapsed or not responded to a prior chemotherapy.

Cerdulatinib for the treatment of b-cell malignancies

Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib.

Cerdulatinib for treating myeloma

Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.

Cerdulatinib for treating hematological cancers

Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.

Growing community of inventors

Emerald Hills, CA, United States of America

Gregory Coffey